Resveratrol

Resveratrol is a stilbenoid phytoestrogen that Ray Peat consistently identified as a dangerous molecule masquerading as an anti-aging therapy, primarily through its fraudulent association with the sirtuin genes and calorie restriction mimetics. 2 Peat argued that the entire premise of resveratrol as a longevity drug rests on the discredited rate of living theory, which wrongly assumes that a lower metabolic rate extends lifespan, and on a fundamental misunderstanding of yeast biology where increased cell division—analogous to cancer in humans—was misinterpreted as longevity. 2 He noted that resveratrol is structurally similar to the synthetic estrogen diethylstilbestrol (DES), a notoriously toxic and carcinogenic pharmaceutical, and that its effects in yeast are simply the result of overdosing an estrogen-sensitive organism to increase its fertility. 2

The molecular mechanism promoted by resveratrol advocates involves the activation of the Sir2/SirT1 gene, a "silent information regulator" that suppresses protein production as a stress response. 2 Peat warned that this process of turning off genes in a human moves the organism toward a spore-like, hibernating state, and critically, two of the proteins silenced by sirtuins are klotho, an anti-aging phosphate-regulating protein, and P53, a crucial tumor-suppressor protein. 2 He further highlighted that resveratrol suppresses mitochondrial respiration, inhibits the formation of the protective hormone progesterone within mitochondria, and interferes with the ability of pancreatic beta cells to secrete insulin. 3 In direct opposition, Peat pointed to niacinamide as a substance that protects mitochondrial respiration, extends the replicative lifespan of human cells in vitro, and was once explicitly warned against by resveratrol promoters for antagonizing sirtuins and supposedly accelerating aging. 2

Georgi Dinkov has extended this critique by detailing the commercial failure and toxicity of resveratrol, noting that GlaxoSmithKline's $720 million acquisition of David Sinclair's company Sirtris ended abruptly when clinical trials for kidney failure resulted in an increased number of deaths in the treatment group, leading to the immediate halt of all research. 3 Dinkov explained that while resveratrol can raise NAD levels, it does so pathologically by speeding up glycolysis and generating lactic acid, effectively promoting a cancer metabolism by using pyruvate as an emergency oxidant rather than supporting proper oxidative phosphorylation through the Krebs cycle. 7 He emphasized that all stilbenoids are potent phytoestrogens that destabilize the cell, making it divide faster and enter a state primed for mutation. 2

Peat also documented that resveratrol's supposed benefits are contradicted by direct experimental evidence, including a study showing it reduced the ability of human keratinocytes to divide, an effect that by the rate-of-living theory's own definitions would constitute premature aging. 3 He observed that the metabolic depression expected from resveratrol—slowed heart rate and lowered body temperature—was only transient in mice, but that the treatment permanently reduced their endurance on a treadmill. 4 The broader cultural acceptance of resveratrol, Peat argued, was manufactured by a culture permeated by genetic determinism and amplified by mass media, obscuring the reality that calorie restriction's effects involve hundreds of genes and that increased SirT1 activity might actually contribute to cancer and Alzheimer's disease. 2